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Abstract
Introduction: Very few studies have investigated whether the time elapsed between surgical resection and tissue
fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured
biomarkers, including phosphorylated proteins in primary breast cancer. The aim of this study was to characterise
the differences in immunoreactivity of common biomarkers that may occur (1) as a result of tissue handling at
surgery and (2) between core-cuts and resected tumours.
Methods: Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after
routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared with the
routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen
receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk1/2 were
investigated.
Results: Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-
cuts A and B was 30 minutes (range, 20 to 80 minutes). None of the markers showed significant differences
between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main
resection specimen, although there was a trend for lower resection values for ER (P = 0.06). However, p-Akt and
p-Erk1/2 were markedly lower in resections than core-cuts (median, 27 versus 101 and 69 versus 193, respectively;
both P < 0.0001 [two-sided]). This difference was significantly greater in mastectomy than in lumpectomy
specimens for p-Erk1/2 (P = 0.01).
Conclusions: The delay in fixation in core-cuts taken after postoperative X-ray of resection specimens has no
significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However, extreme loss of phospho-
staining can occur during routine fixation of resection specimens. These differences are likely attributable to
suboptimal fixation and may have major repercussions for clinical research involving these markers.
Introduction
Stratification of therapy is a prime goal of current
research. Tissue biomarkers are expected to provide
indices enabling selection of therapy. Assurance of the
validity of biomarker measurement is critical for their
accurate application and interpretation, particularly in
the context of presurgical studies, which are being
increasingly used to speed drug development [1].
A variety of tissue sample types (e.g., core-cuts, punch
biopsies, excisions) are used in biomarker studies, and
comparative measurements of a marker between tissue
types may occur within a single trial (e.g., core-cut at
diagnosis/pretreatment versus excision/posttreatment).
There are, however, few data available on the impact of
sample type, even for frequently measured biomarkers
such as Ki67, which has been used as a primary end
point of some trials [2]. It is essential that any differences
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any medium, provided the original work is properly cited.that arise from the expression of such markers in trials
should be solely attributable to the effect of treatment
with the drug and not due to potential artefacts such
as those caused by delays to tissue fixation in different
sample types.
Protein kinases are targets for approximately one third
of drugs in development for oncology. Their phosphory-
lated products provide pharmacodynamic end points
during clinical development and are likely, at least in
some cases, to be determinants/indices of treatment
efficacy and thus to become biomarkers in routine prac-
tice. Some previous studies have indicated that some
phosphoproteins are labile during fixation [3,4]. We
undertook a systematic assessment of immunoreactive
expression of several established or developmental
biomarkers for breast cancer, including two centrally
important phosphorylated proteins: p-Akt and p-Erk1/2.
To address these issues, we evaluated two situations
that arise in the increasingly popular “window of oppor-
tunity” studies in primary breast cancer that exploit the
approximately 2 weeks between diagnosis and surgery:
(1) the delay of starting fixation between tumour exci-
sion and its return to theatre after X-ray to assess calci-
fication and margin clearance, and (2) differences
between core-cuts fixed immediately on tumour resec-
tion and histopathological sections from routinely fixed
primary breast cancers.
Materials and methods
Sample collection
Twenty-eight patients were studied at resection of
primary breast cancer; 29 specimens were available (one
patient with two tumours). Basic demographics were
median age, 54 years; median tumour size, 29 mm; lum-
pectomy versus mastectomy, 16 versus 13, respectively;
node negative versus positive, 16 and 12, respectively
(one was not available). Two 14-gauge core-cuts were
taken immediately after tumour resection (sample A);
one was placed in neutral-buffered formalin and one
into RNAlater (Applied Biosystems/Ambion, Austin,
TX, USA). The tumour was sent for X-ray at ambient
temperature; on return to theatre after a recorded time,
two more core-cuts were taken and handled similarly
(sample B). The resected specimen (sample C) was
placed in formalin and subjected to the histopathology
department’s routine fixation for breast tumours: lum-
pectomy specimens were left unsliced until the next
morning, and mastectomy specimens were sliced at
intervals of about 10 mm to allow penetration of forma-
lin. Radioactive specimens were left unsliced for 48
hours to allow for isotope decay. Ethical approval was
provided by the Royal Marsden Hospital (RMH). All
patients gave written, informed consent.
Immunohistochemical determination of Ki67, ER, PgR,
HER2, p-Akt and p-Erk1/2
Four-micron sections of formalin-fixed, paraffin-
embedded (FFPE) tissues were deparaffinised in xylene
for 5 minutes and gradually rehydrated in decreasing
grades (100%, 90%, 80% and 70%) of industrial methy-
lated spirits (IMS) and water washes. Table 1 provides
further details of the immunohistochemical methodol-
ogy used for all markers. In all cases, endogenous perox-
idase blocking, incubation with primary and secondary
antibodies and signal amplification and detection steps
of the immunohistochemical procedure were conducted
on the Autostainer Immunostaining System (Dako, Car-
pinteria, CA, USA). Slides were then washed in running
tap water for 5 minutes, counterstained in Mayer’sh a e -
matoxylin for 1 minute and washed again for 5 minutes.
Sections were dehydrated in gradual IMS washes (70%,
80%, 90% and 100%), incubated twice in xylene for 5
minutes and mounted on the CTM6 Glass Coverslipper
(Thermo Fisher Scientific/Microm, Walldorf, Germany).
All sections within the same set (i.e., samples A, B and
C) were stained in the same batch to minimise any
batch-to-batch variations that might occur which could
affect staining intensity and lead to erroneous results.
Assessment of p-Akt, p-Erk1/2, ER and PgR expression
across 10 high-power fields was done by H score, in which
the percentage of invasive cells staining in each intensity
category (0, zero; 1, faint; 2, moderate; or 3, strong) was
derived, multiplied by its intensity and summed (range,
0-300). Ki67 expression was assessed by percentage of
positive invasive cells staining in any category 1-3 (percen-
tage positive score) across 10 high-power fields. HER2
assessment was done by IHC categories 0, 1+, 2+ and
3+ as per HercepTest™ (DakoCytomation, Glostrup, Den-
mark) and the American Society of Clinical Oncology/
College of American Pathologists (ASCO/CAP) guidelines
[5]. The assessment of all markers was blinded with regard
to sample time point and sample set.
Statistical analysis
Comparison of IHC scores between samples A, B and C
was conducted using the Wilcoxon signed-rank test.
Spearman regression analyses were conducted between
the difference in expression between samples A and B
and the time elapsed between their collection. Data
from samples placed in RNAlater will be published
separately. P values were two-sided.
Results
Twenty complete sets of samples with adequate invasive
tissue and one set missing sample B were available. Med-
ian time from collection of samples A and B was 30 min-
utes (range, 20-80 minutes). No significant differences
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p-Akt, p-Erk1/2 or HER2 (Table 2). There were no
significant correlations between time elapsed and the
differences between samples A and B (all P > 0.20). Com-
parisons with sample C were therefore made with mean
expression values for samples A and B (mean A,B).
There were no significant differences between these
scores for Ki67, ER and PgR, although a trend to a lower
ER value in the resection was seen (Figure 1a, P = 0.19;
Figure 1b, P = 0.06; and Figure 1c, P = 0.89, respectively).
For HER2, 12 of 15 cases categorised as 1+ on at least one
of sample A or B were scored 0 in the resection, but no
differences in HER2 positive or negative status occurred
(Figure 1d). However, p-Akt and p-Erk1/2 were highly sig-
nificantly lower in sample C than in mean A,B (Figures 2a
and 2b, respectively; P < 0.0001). Near-complete absence
of staining (H score <5) occurred in 6 of 21 samples C
for p-Akt and 8 of 21 for p-Erk1/2, despite mean A,B
values for some of these being among the highest. None-
theless, there was a significant correlation between values
for mean A,B and C samples for both phosphoproteins
(R = 0.68, P =0 . 0 0 0 8 ;R = 0.52, P = 0.015, respectively).
The mean difference in staining between mean A,B
and C samples was greater for both phosphoproteins in
mastectomy than lumpectomy samples (Figures 3a and
3b), but only significantly so for p-Erk1/2 (P = 0.01).
Discussion
The data described reveal that the immunohistochemical
detection of certain biomarkers is highly comparable
Table 1 Details of the immunohistochemical procedure used for each marker*
IHC
procedure
Antigen
Retrieval
Endogenous
Peroxidase
Blocking
Monoclonal
Antibody
Secondary
Antibody
Signal
Amplification
Signal
Detection
Kit used
p-Erk1/2 Preheated target
retrieval solution
(1×), water bath
97 ± 2°C, 30 min
Phosphate buffer
containing
hydrogen
peroxide, 5 min
Phospho-p44/42
MAPK (Erk1/2)
(Thr202/Tyr204);
(1:100) (Cell Signalling,
#4376), 1 h
Rabbit linker, 15
min
Polymer conjugated
to horseradish
peroxidase (HRP)
and goat antirabbit
and antimouse
immunoglobulin, 30
min
EnVision™
FLEX+
(Dako)
p-Akt Phospho-Akt (Ser473);
(1:25) (Cell Signalling,
#3787), 1 h
Ki67 Preheated 0.01 M
citrate buffer pH
6.0, microwave
800 W, 10 min
Clone MIB-1 (1:40)
(Dako), 20 min
Biotinylated goat
antimouse and
antirabbit
immunoglobulins,
15 min
Streptavidin
conjugated to HRP,
15 min
DAB
(chromogen)
in hydrogen
peroxide
(substrate), 10
min
Real™ (Dako)
ER Clone 6F11 (1:40)
(Novocastra), 20 min
PgR Clone 16 (1:100)
(Novocastra), 20 min
HER2 Preheated 0.01 M
citrate buffer,
water bath 97 ±
2°C, 40 min
3% hydrogen
peroxide, 5 min
Rabbit antihuman
HER2 protein, 30 min
Polymer conjugated to HRP and goat
antirabbit immunoglobulin, 30 min
HercepTest™
(Dako)
*ER, oestrogen receptor: PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HRP, horseradish peroxidase, DAB, 3,3’-diaminobenzidine.
Table 2 Median (interquartile range) expression of markers ER, PgR, Ki67, p-Akt and p-Erk1/2 in samples A, B and C as
defined in the text*
Marker Sample A Sample B Sample C P value
Ki67 16.4 (9.4-21.7) 17.1 (7.0-25.1) 15.3 (8.0-19.6) 0.19
ER 190.4 (171.2-200.5) 194.7 (167.6-199.4) 188.0 (145.1-195.4) 0.06
PgR 158.9 (58.3-193.3) 161.0 (97.2-189.0) 153.3 (42.2-193.2) 0.89
HER2 3+: 1; 2+: 2; 1+: 14; 0: 4 3+: 1; 2+: 2; 1+: 13; 0: 4 3+: 1; 2+: 2; 1+: 3; 0: 15 0.0012
p-Akt 111.4 (60.8-178.6) 101.1 (75.4-146.0) 26.8 (5.0-75.4) <0.0001
p-Erk1/2 212.2 (123.6-243.6) 193.1 (113.5-238.0) 69.3 (0.4-113.5) <0.0001
*Numerical values for samples A, B and C refer to H scores (for ER, PgR, p-Erk1/2 and p-Akt) and percentage positive scores (for Ki67). For HER2, the number of
cases in each staining category is shown. P values refer to comparison between mean A, B and C samples. ER, oestrogen receptor: PgR, progesterone receptor;
HER2, human epidermal growth factor receptor 2.
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Page 3 of 7Figure 1 Expression of commonly assessed markers in breast cancer specimens by immunohistochemistry (IHC). Expression of (a) Ki67,
(b) ER, (c) PgR and (d) HER2 in core-cuts (mean of samples A and B) and resections (sample C).
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The modest difference in ER and the lack of difference
in Ki67 and PgR is consistent with the absence of a dif-
ference between core-cuts and resection samples in the
placebo arm of some of our earlier reports on short-
term presurgical studies [6,7]. While there was no effect
on the p-Akt or p-Erk1/2 staining over the 20- to
80-minute delay in fixation of core-cuts, the difference
between core-cuts and excision samples was extreme
and could lead to major erroneous interpretation. For
example, if these results were obtained in a “window-of-
opportunity” trial that included only a treatment arm,
they could be taken as strong evidence of the pharmaco-
logical effectiveness of that treatment.
The differences between core-cut and excision sam-
ples could be influenced by sampling differences of
heterogeneously expressed markers but are most likely
due to differences in time to fixation: the correlation
between core-cut and excision values indicates a sys-
tematic difference. At room temperature and without
fixation accelerators, formalin, by far the most widely
used histopathological fixative, penetrates tissue at
approximately 1 mm/hour [8]. Thus fixation will be
initiated rapidly throughout core-cuts (small volume)
after immersion whilst penetration of the larger
volume main specimen will be slower, resulting in
greater loss of biomarker expression. Manoeuvres are
therefore necessary to allow rapid initiation of fixation
throughout excision biopsies. This is further supported
by the reduction in phospho-staining between cores
and the main resection being more noticeable in mas-
tectomy than in lumpectomy specimens, especially for
p-Erk1/2.
We recently reported that the routine fixation proce-
dure at RMH provides excellent correlations for ER
and HER2 status (i.e., positive or negative) between
Figure 2 Expression of phosphoproteins in core-cuts and excisions according to type of surgical specimen. (a) p-Akt and (b) p-Erk1/2
expression by IHC in core-cuts (mean of samples A and B) and resection (sample C).
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results are supported here [9]. Approximately 15% dis-
cordance was noted for PgR in that study on the basis
of positive-negative categorisation. Using the cutoff of H
score 20, no such discordance was seen in the current
study, but the numbers of subjects are too low to
exclude that level of discordance. The trend to a quanti-
tative difference reported here for ER and the significant
difference we reported previously between excisions
and cores are unlikely to lead to erroneous exclusion
of responsive patients from endocrine therapy [6].
However, recent data indicate that quantitative levels of
E Rm a yb eu s e f u l l yi n c o r p o r a t e di n t oa l g o r i t h m sf o r
predicting patient outcome [10]; such assessments will
benefit from optimal fixation procedures.
The major differences seen in the two phosphoproteins
have major implications for clinical research and future
patient management. Past research reports that assessed
expression of these markers in samples without special
attention to fixation, including studies from our own
group [11], may have reached erroneous conclusions
[12-19]. One recent publication on p-Akt in relation to
the clinical benefit of paclitaxel in the adjuvant treatment
of breast cancer recognised the potential for loss of immu-
noreactivity because of variations in specimen fixation; an
optimised antigen retrieval technique was stated to have
been used, but its effectiveness was not reported [20].
False-negative results (when inconsistent fixation has
occurred) or false-positive results (when systematic bias
has resulted from consistently different fixation as alluded
to above for window-of-opportunity studies) may both
occur. There are also implications for future clinical man-
agement: if any such labile markers emerge, as is antici-
pated, from current translational research efforts, stored
routinely fixed tissues are unlikely to be valid for their
measurement. Although guidelines for optimal fixation
have been published [5], it is clear that these are not uni-
formly adhered to. This practice needs to be markedly
improved to prepare for clinical application of future
agents.
Conclusions
Immunohistochemical staining for ER, PgR, HER2 and
Ki67 is similar between core-cuts and excision biopsies
Figure 3 Expression of p-Akt and p-Erk1/2 in lumpectomy versus mastectomy specimens. Percentage difference between resections
(sample C) and core-cuts (mean of samples A and B) expression values for (a) p-Akt and (b) p-Erk1/2. Percentage difference defined as (sample
C - mean of samples A and B) × 100/mean of samples A and B.
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tinely fixed excisions. This effect could lead to both
false-negative and false-positive findings according to
study design and should be considered both in study
design and when interpreting published data.
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